A BUDGET-IMPACT ANALYSIS (BIA) OF IMMUNIZING ADULTS WITH COPD WITH THE 13-VALENT VACCINE (PCV13) AGAINST COMMUNITY- ACQUIRED PNEUMONIA AND PNEUMOCOCCAL DISEASE

被引：0
|
作者：
Walter, E. [1 ]
Lazic-Peric, A. [1 ]
Schalle, K. [1 ]
机构：
[1] Inst Pharmaecon Res, Vienna, Austria
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.2279
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN25
引用
收藏
页码：A783 / A783
页数：1
相关论文
共 50 条
  • [1] 13-Valent pneumococcal conjugate vaccine (PCV13) serotypes in adults with community acquired pneumonia in Taiwan
    Chang, S. C.
    Li, C. T.
    Cheng, S. L.
    Gray, S.
    Gonzalez, E.
    Pride, M.
    Sebastian, S.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 45 : S119 - S119
  • [2] 13-valent pneumococcal conjugate vaccine (PCV13)
    Jefferies, Johanna M. C.
    Macdonald, Emily
    Faust, Saul N.
    Clarke, Stuart C.
    HUMAN VACCINES, 2011, 7 (10): : 1012 - 1018
  • [3] Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska
    Bruce, Michael G.
    Singleton, Rosalyn
    Bulkow, Lisa
    Rudolph, Karen
    Zulz, Tammy
    Gounder, Prabhu
    Hurlburt, Debby
    Bruden, Dana
    Hennessy, Thomas
    VACCINE, 2015, 33 (38) : 4813 - 4819
  • [4] A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly
    Dirmesropian, S.
    Wood, J. G.
    MacIntyre, C. R.
    Newall, A. T.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (04) : 818 - 825
  • [5] Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan
    Shen, Ching-Fen
    Chen, Ju-Ling
    Su, Chien-Chou
    Lin, Wen-Liang
    Hsieh, Min-Ling
    Liu, Ching-Chun
    Cheng, Ching-Lan
    VACCINES, 2021, 9 (09)
  • [6] Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States
    Rubin, Jaime L.
    McGarry, Lisa J.
    Strutton, David R.
    Klugman, Keith P.
    Pelton, Stephen I.
    Gilmore, Kristen E.
    Weinstein, Milton C.
    VACCINE, 2010, 28 (48) : 7634 - 7643
  • [7] 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Preterm Versus Term Infants
    Martinon-Torres, Federico
    Czajka, Hanna
    Center, Kimberly J.
    Wysocki, Jacek
    Majda-Stanislawska, Ewa
    Omenaca, Felix
    Bernaola Iturbe, Enrique
    Blazquez Gamero, Daniel
    Concheiro-Guisan, Ana
    Gimenez-Sanchez, Francisco
    Szenborn, Leszek
    Giardina, Peter C.
    Patterson, Scott
    Gruber, William C.
    Scott, Daniel A.
    Gurtman, Alejandra
    PEDIATRICS, 2015, 135 (04) : E876 - E886
  • [8] Impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia and pneumococcal pneumonia in children in Japan
    Ishiwada, Naruhiko
    Naito, Sachiko
    Takeuchi, Noriko
    Ohkusu, Misako
    Nagasawa, Koo
    Abe, Katsuaki
    Omata, Yuko
    Hishiki, Haruka
    Hoshino, Tadashi
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 : S46 - S46
  • [9] ECONOMIC IMPACT IN DOMINICAN REPUBLIC SENASA OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) VERSUS NO VACCINATION IN OLDER ADULTS
    Del Villar-Tapia, Y.
    Brito-Tayson, G.
    Lizardo, J.
    VALUE IN HEALTH, 2020, 23 : S173 - S173
  • [10] Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians
    Dirmesropian, S.
    Wood, J. G.
    MacIntyre, C. R.
    Beutels, P.
    McIntyre, P.
    Menzies, R.
    Reyes, J. F.
    Chen, C.
    Newall, A. T.
    VACCINE, 2017, 35 (34) : 4307 - 4314
12345